Massive blood loss in adult jehovah´s witness Patient
##plugins.themes.bootstrap3.article.main##
Major bleeding (MB) is defined as the loss of volume over a less-than-24-hour period of time or the loss of 50% of volume in a less-tha-3-hour time in a previously healthy individual. Considering the firm determination to reject any transfusion of blood or blood components on the part of Jehovah's Witnesses, the management of major bleeding in them is a challenge whether in emergency room or surgery services. This fact has serious ethical and legal implications. Preventing major bleeding in Jehovah's Witnesses allows the introduction of preventive measures to hypovolemic shock. For the treatment of Jehovah's Witness patients having major bleeding, therapeutic targets are proposed including the implementation of hemostatic or pharmacological interventions during surgical treatment; likewise in the postoperative period it is proposed appropriate hemodynamic and mechanic ventilation goals. It is a narrative review of the last 10-year literature and preventive actions, therapeutic goals and different interventions currently at disposal to deal with MB are presented.
Downloads
##plugins.themes.bootstrap3.article.details##
The Royal College of Surgeons of England. 2002. Code of practice for the surgical management of Jehovah’s witnesses Published by the Royal College of Surgeons of England.
¿Cómo puede salvarle la vida la sangre? 1990. Watch Tower Bible and Tract Society Pennsylvania, New York Inc. Revista Atalaya.
Jiménez C.E. 2005. Recomendaciones medicoquirúrgicas para disminuir el uso y pérdida de derivados sanguíneos. Revista Colombiana de Cirugía. 20(2).
Nash M.J. 2004. Hannah Cohen Management of Jehovah’s Witness patients with haematological problems. Blood Reviews 18:211-217.
Beauchamp T, Childress J. F. 1999. Principios de ética biomédica. Masson, S.A. Barcelona. http://intensivos.uninet.edu/03/0301.html.
Sentencia T-659/02 Referencia: expediente T-589908. Bogotá, D. C., quince (15) de agosto de dos mil dos (2002).
British Committee for Standards in Haematology: Writing Group: D. Stains by, S. MacLennan, D. Thomas, J. Isaac and P. J. Hamilton 4 Guide lines on the anagement of massive blood loss. doi:10.1111/j.1365-2141.2006.06355.x Journal Compilation a 2006 Blackwell Publishing Ltd, British Journal of Haematology, 135:634-641.
Kenrick Berend, MD, Ph D, Marcel Levi, MD, PhD. 2009. Management of Adult Jehovah’s Witness Patients with Acute Bleeding. The American Journal of Medicine 122:1071-1076.
Donat R. Spahn, Vladimir Cerny, Timothy J Coats, Jacques Duranteau, Enrique Fernández- Mondéjar, Giovanni Gordini, Philip F Stahel, Beverley J Hunt, Radko Komadina, Edmund Neugebauer, Yves Ozier, Louis Riddez, Arthur Schultz, Jean- Louis Vincent and Rolf Rossaint. 2007. Management of bleeding following major trauma: a European Guideline. Published: 13 Feb 2007. Critical Care 11:R17 (doi:10.1186/cc5686) This articles on line at: http://ccforum.com/content/11/1/R17
Zenon M. Bodnaruk, Colin J. Wong, and Mervyn J. Thomas. 2004. Meeting the Clinical Challenge of Care for Jehovah’s Witnesses Transfusion Medicine Reviews, 18(2):105-116.
Jiménez J. CE. 2005. Recomendaciones médico-quirúrgicas para disminuir el uso y pérdida de derivados sanguíneos. Revista Colombiana de Cirugía. 20(2).
Mcdougall IC, Ashenden M. 2009. Current and up comin gery thro poiesis-stimulatin gagents, iron products, and other novel anemia medications. Adv. Chronic Kidney Dis 16(2):117-130.
Guyton.
Omar Dary. 2009. Nutrition Science Policy Nutrition all interpretation of folic acid interventions. International Life Sciences Institute. Nutrition Reviews® 67(4):235-244.
Patrick J. Stover. 2010. Vitamin B12 and older adults. Current Opinion in Clinical Nutrition and Metabolic Care 13:24-27.
Tarng DC. 2007. Novel aspects of vitamin C in epoetin response. J Chin Med Assoc 70(9):357-360.
Faris P, Spende K, Larholt M. 1999. The predictive power of base line hemoglobin for transfusion risk in surgery patients.
Orthopedics 22(suppl):s135-s140.
Macintyrea. 1992. Blood transfusion and hemostatic management in the perioperative period. Can J Anaesth 39: Pt 2, R101-114.
De Jonge E, Levi M. 2001. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med. 29:1261-1267.
Purdham RS. 1996. Reduced blood loss with hemodynamic stability during controlled hypotensive anesthesia for Lefort I. Maxillary osteotomy using high dose fentanyl: a retrospective study. CRNA 33-46.
Jones R, Moulton M. 1998. Central venous pressure and its effect on blood loss during liver resection. Br J Surg 85:1058-1060.
Jonathan H. Waters, MD. 2005. Red Blood Cell Recovery and Reinfusion Anesthesiology Clinics of North America 23:283-294.
Terri G. Monk, MD. 2005. Acute Normovolemic Hemodilution Anesthesiology Clin N Am 23:271-281.
Lawrence T. Goodnough, MD. 2005. Autologous Blood Donation Anesthesiology Clin N Am 23:263-270.
Christopher J. Dunn andKaren L. Goa. 1999. Tranexamic Acid A Review of its Use in Surgery and Other Indications. Adis International Limited, Auckland, New Zealand - Drugs 57(6):1005-1032.
David Henry MB Ch.B, Paul Carless BH Sc M Med Sc (ClinEpid), Dean Fergusson PhD MHA, Andreas Laupacis MD MSc. 2009. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a metaanalysis. CMAJ 180(2).
Kerstin S Schick, Jan M Fertmann, Karl-Walter Jauchand Johannes N Hoffmann. 2009. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonis treversa land treatment of severe bleeding. Critical Care 13:R191(doi:10.1186/cc8186).
Cindy A. Leissinger, Philip M. Blatt W. 2008. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Keith Hoots and Bruce Ewenstein Am J Hematol 83:137-143.
Bulent O, Zgonenel, Madhvi Rajpurkar, Jeanne M Lusher. 2007. How do you treat bleeding disorders with desmopressin?. Postgrad Med J 83:159-163. doi: 10.1136/pgmj.2006.052118.
Nigel Mackman, PhD. 2009. The Role of Tissue Factor and Factor VIIa in Hemostasis. From the Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Anesth Analg. 108(5):1447-1452. doi:10.1213/ane. 0b013e31819bceb1.
Paula F. Moon-Massat, DVM, Aryeh Shander, MD, Mazyar Javidroozi, MD, and A. Gerson Greenburg. 2010. When Bloodis Notan Option: Factors Affecting Survival After the Use of a Hemoglobin-Based Oxygen Carrier in 54 Patients with Life-Threatening Anemia Colin F. Mackenzie, MB ChB, FRCA, FCCM,*MD 110(3). www.anesthesia-analgesia.org